[go: up one dir, main page]

AU2001228742A1 - Ligand for vascular endothelial growth factor receptor - Google Patents

Ligand for vascular endothelial growth factor receptor

Info

Publication number
AU2001228742A1
AU2001228742A1 AU2001228742A AU2874201A AU2001228742A1 AU 2001228742 A1 AU2001228742 A1 AU 2001228742A1 AU 2001228742 A AU2001228742 A AU 2001228742A AU 2874201 A AU2874201 A AU 2874201A AU 2001228742 A1 AU2001228742 A1 AU 2001228742A1
Authority
AU
Australia
Prior art keywords
ligand
growth factor
vascular endothelial
factor receptor
endothelial growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228742A
Inventor
Valery Alakhov
Shengmin Li
Grzegorz Pietrzynski
Lioudmila Tchistiakova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supratek Pharma Inc
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of AU2001228742A1 publication Critical patent/AU2001228742A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001228742A 2000-02-04 2001-02-02 Ligand for vascular endothelial growth factor receptor Abandoned AU2001228742A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18056800P 2000-02-04 2000-02-04
US60180568 2000-02-04
PCT/IB2001/000135 WO2001057067A1 (en) 2000-02-04 2001-02-02 Ligand for vascular endothelial growth factor receptor

Publications (1)

Publication Number Publication Date
AU2001228742A1 true AU2001228742A1 (en) 2001-08-14

Family

ID=22660933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228742A Abandoned AU2001228742A1 (en) 2000-02-04 2001-02-02 Ligand for vascular endothelial growth factor receptor

Country Status (6)

Country Link
US (2) US6733755B2 (en)
EP (1) EP1252177A1 (en)
JP (1) JP2003528824A (en)
AU (1) AU2001228742A1 (en)
CA (1) CA2399022A1 (en)
WO (1) WO2001057067A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363568A1 (en) * 1999-03-04 2000-09-08 Kyowa Hakko Kogyo Co., Ltd. Diagnostic agent and therapeutic agent for leukemia
CA2399022A1 (en) * 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
ES2260234T3 (en) * 2000-05-12 2006-11-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. USE OF INHIBITORS OF THE PLACENTARY GROWTH FACTOR FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS, PATHOLOGICAL ARTERIOGENESIS, INFLAMMATION, TUMORAL FORMATION AND / OR VASCULAR LOSS.
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
CA2513044A1 (en) * 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
CN100475269C (en) * 2002-03-05 2009-04-08 北京键凯科技有限公司 Binding agent of hydrophilic polymer-glutamic acid oligopeptide and medicinal molecular, composition containing said binding agent and use thereof
EP1496076B1 (en) 2002-03-13 2007-07-25 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
CU23178A1 (en) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech ANTIANGIOGEN ACTIVE ACTIVE IMMUNOTHERAPY
DK2949658T3 (en) * 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
US20050277575A1 (en) * 2004-03-24 2005-12-15 Alexandre Semov Therapeutic compositions and methods for treating diseases that involve angiogenesis
DK1869085T3 (en) * 2005-03-24 2012-06-18 Thrombogenics Nv Hitherto unknown anti-PLGF antibody
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
WO2007062105A2 (en) * 2005-11-21 2007-05-31 The Trustees Of Columbia University In The City Of New York Multiplex digital immuno-sensing using a library of photocleavable mass tags
US7531505B2 (en) * 2006-01-11 2009-05-12 Affinergy, Inc. Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
CN101534793A (en) * 2006-11-06 2009-09-16 诺瓦提斯公司 Ocular devices and methods of making and using thereof
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US20110150837A1 (en) * 2009-12-23 2011-06-23 Flamel Technologies Amphiphilic polymer functionalized by methionine
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
PL2785739T3 (en) 2011-12-01 2017-10-31 Thrombogenics Nv Improving trabeculectomy outcome
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2017200173A1 (en) * 2016-05-19 2017-11-23 삼성전자 주식회사 Vegf-binding fragment mutant, and fusion protein comprising vegf-binding fragment mutant and anti-c-met antibody
US11702462B2 (en) 2017-07-19 2023-07-18 Rutgers, The State University Of New Jersey Gene transfer systems for stem cell engineering

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870160A (en) * 1987-08-19 1989-09-26 Regents Of The University Of Minnesota Polypeptides with laminin activity
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
EP0882799B1 (en) * 1996-11-21 2006-06-28 Kyowa Hakko Kogyo Kabushiki Kaisha Anti-human vegf receptor flt-1 monoclonal antibody
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
AU767731B2 (en) * 1998-05-20 2003-11-20 Kyowa Hakko Kirin Co., Ltd. Gene recombinant antibodies
AU3897200A (en) * 1999-03-18 2000-10-04 Hope Heart Institute, The Endothelial cell stimulation by a complex of fibronectin and vascular endothelial growth factor
CA2399022A1 (en) * 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor

Also Published As

Publication number Publication date
CA2399022A1 (en) 2001-08-09
US7112654B2 (en) 2006-09-26
US6733755B2 (en) 2004-05-11
EP1252177A1 (en) 2002-10-30
JP2003528824A (en) 2003-09-30
WO2001057067A1 (en) 2001-08-09
US20040266694A1 (en) 2004-12-30
US20020058619A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
AU2001228742A1 (en) Ligand for vascular endothelial growth factor receptor
AU2002252631A1 (en) Vascular endothelial growth factor 2
AU5023300A (en) Vascular endothelial growth factor variants
AU2001246835A1 (en) Ethylenediamine derivatives
AU1486401A (en) Shelving bracket
AU2002256172A1 (en) Vascular endothelial growth factor 2
AU1897700A (en) Removable stent
AU1290001A (en) Antibodies
AU2001281758A1 (en) Biocompatible materials
EP1313512A4 (en) Vascular endothelial growth factor 2
AUPR030900A0 (en) Growth factor complex
AUPQ910500A0 (en) Support means
AU4935000A (en) Antibodies
AU2001236179A1 (en) Supporting arm for surgical purposes
AU2001284048A1 (en) Support beam
AU6202500A (en) Durable multilayer nonwoven materials
AU2722400A (en) Real-time planner for design
AU5319700A (en) Nicotine receptor ligands
AU2001259195A1 (en) Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
AU5026100A (en) Vascular endothelial growth factor dimers
AU2002212374A1 (en) Automatic dispenser
AU2001288392A1 (en) Delivery system for heparin-binding growth factors
AU2001240557A1 (en) Implant for cranioplastics
AU2002313770A1 (en) Vascular endothelial growth factor 2
AU4781100A (en) Ip3 receptor ligands